In 2024, three further VGF fragments [68], PPGRPEAQPPPLSSEHKEPVAGDAVPGPKDGSAPEVRGA, AVPGPKDGSAPEV, and APPEPVPPPRAAPAPT, or PPGR-39, AVPG-13, and (N)APPE-19, at proVGF 24–62, 47–59, and 487–504, respectively, were decreased in CSF samples from ALS patients (n = 50) compared to non-ALS controls (n = 50; patients without neurodegenerative diseases who underwent lumbar puncture for differential diagnosis of facial palsy or headaches). This evidence concerns the gene VGF and neurodegenerative disease.